1515
Annons
Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2021
Third quarter (July-September 2021)
  • Operating loss totaled SEK -6,753,799 (-216,550).
  • Loss for the period totaled SEK -6,753,799 (-211,132).
  • Cash flow from operating activities totaled SEK -13,418,888 (-104,589).
  • Earnings per share before dilution totaled SEK -0.34 (-0.02). Earnings per share after dilution amounted to SEK -0.34 (-0.02).
Period (January-September 2021)
  • Operating loss totaled SEK -10,977,101 (-232,020).
  • Loss for the period totaled SEK -10,978,176 (-226,601).
  • Cash flow from operating activities totaled SEK -13,413,256 (-122,627).
  • Earnings per share before dilution totaled SEK -0.75 (-0.02). Earnings per share after dilution totaled SEK -0.75 (-0.02).
Key events during the third quarter
  • The Board of Directors and executive management of Elicera Therapeutics increased their holdings and pur­chased shares.
  • Elicera Therapeutics presented the results of its research at the European Society of Gene & Cell Therapy (ESGCT) 2021 Virtual Congress on October 19-21, and at the 13th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit on November 2-4.
Significant events during the period
  • The Board of Directors was expanded with the addition of cell therapy specialist Karin Hoogendorn.
  • Elicera conducted a new share issue that attracted a great deal of interest and generated proceeds of SEK 55.1 million net after costs.
  • Elicera was listed on Nasdaq First North Growth Market on 11 June.
  • G&W appointed Certified Adviser.
  • Elicera Therapeutics submitted a patent application for devel­opment of ELC-201, the next generation of oncolytic viruses.
  • Elicera Therapeutics received ATMP classification from the EMA for the oncolytic virus ELC-100.
Key events after the end of the period
  • Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor.
  • Nomination Committee for Elicera Therapeutics appointed with Magnus Essand as chairman.
  • Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy.
  • No other key events that impact earnings or the financial position occurred after the end of the perio

CEO Comments

Our iTANK technology platform was developed for CAR T-cells to generate a dual attack on cancer.

In addition to our broad portfolio of immuno-oncology drug candidates, we have a another very important asset in our fully developed technology platform, iTANK (immunoTherapies Activated with NAP for efficient Killing). iTANK was originally developed to boost the effect of our own immuno-oncology treatments by overcoming some of the greatest challenges of CAR T-cell therapies for the treatment of solid tumors, namely insufficient efficacy and the development of resistance. Re­cently, we presented preclinical data that provided us with the proof of concept for the technology at the European Society of Cell & Gene Therapy, the largest European congress in the field. Our data shows that we boost the efficacy of CAR T-cells with iTANK regardless of the choice of CAR molecule, tumor type or mouse model. This indicates that the platform is universally compatible with other CAR T technologies as well. We thus have favorable conditions to begin market­ing the platform in the autumn, with the long-term goal of establishing several partnerships with other     CAR T companies specifically around iTANK.

To date, seven patients have been treated in the first part of the ongoing Phase I/II trial with ELC-100, our oncolytic virus for treatment of neuroendocrine tumors. The patients were treated at Uppsala University Hospital, but we are also investigating the possibility of starting up yet another clinic abroad in order to accelerate patient recruitment. The safety data will be reported after each patient group - or cohort - has been fully treated in the study.

For our most advanced CAR T project, ELC-301 for the treatment of B cell lymphoma, we have begun GMP production of vectors for the manufacture of CAR T cells. It is estimated that production will be complete by next summer. We are also in the final phase of deciding on the design of the study, which will subsequently be discussed with the Swedish Medical Products Agency.

Our other projects, ELC-201 and ELC-401, are developing in accordance with plans. We recently signed a contract manufacturing agreement with BioNTech around ELC-401. BioNTech will produce the virus vectors to be used in the CAR T-cell constructs for our upcoming clinical phase I/II-study to be intiated in 2023. For ELC-201, the next generation of our oncolytic virus that is applicable for treatment of most forms of cancer, it remains to select the first and most clinically interesting indication. An analysis will be conducted next year. ELC-401 is our CAR T-cell therapy that can be used in the treatment of a range of different solid tumors, but initially we will be treating patients with cancer of the brain (glioblas­toma). To confirm the potential in other indications of solid cancer as well, we will be screening different tumor cells for the target that ELC-401 is directed against, an effort that will be completed during the coming year.

Jamal El-Mosleh

CEO and co-founder

The interim report has been approved by the board and the CEO for publication. The information was submitted for publication distributed through the contact person below at 08;45 CET on November 18, 2021.

Elicera Therapeutics AB's interim report for January to September 2021 is available at the company home page : https://www.elicera.com/investors-2/financial-reports.

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera